Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

An oral NaV1.8 blocker improves motor function in mice completely deficient of myelin protein P0

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. DNA methylation regulates CHRNA7 transcription and can be modulated by valproate

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Acetazolamide lowers intracranial pressure and modulates the cerebrospinal fluid secretion pathway in healthy rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Serotonergic projections from the raphe nuclei to the subthalamic nucleus; a retrograde- and anterograde neuronal tracing study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Neurologiske Sygdomme

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiUndervisning

  2. An in vivo Mouse Model to Investigate the Effect of Local Anesthetic Nanomedicines on Axonal Conduction and Excitability

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Nerve excitability in the rat forelimb: a technique to improve translational utility

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sensation, mechanoreceptor, and nerve fiber function after nerve regeneration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Progression of motor axon dysfunction and ectopic Nav1.8 expression in a mouse model of Charcot-Marie-Tooth disease 1B

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Mice deficient of myelin protein P0 are established models of demyelinating Charcot-Marie-Tooth (CMT) disease. Dysmyelination in these mice is associated with an ectopic expression of the sensory neuron specific sodium channel isoform NaV1.8 on motor axons. We reported that in P0+/-, a model of CMT1B, the membrane dysfunction could be acutely improved by a novel oral NaV1.8 blocker referred to as Compound 31 (C31, Bioorg. Med. Chem. Lett. 2010, 20, 6812; AbbVie Inc.). The aim of this study was to investigate the extent to which C31 treatment could also improve the motor axon function in P0-/-, a CMT model with a much more severe neuropathy. We found that the progressive impairment of motor performance from 1 to 4 months of age in P0-/- could be acutely reversed by C31 treatment. The effect was associated with an improvement of the amplitude of the plantar CMAP evoked by tibial nerve stimulation. The corresponding motor nerve excitability studies by "threshold tracking" showed changes after C31 consistent with attenuation of a resting membrane depolarization. Our data suggest that the depolarizing motor conduction failure in P0-/- could be acutely improved by C31. This provides proof-of-concept that treatment with oral subtype-selective NaV1.8 blockers could be used to improve the motor function in severe forms of demyelinating CMT.

OriginalsprogEngelsk
TidsskriftNeuroscience Letters
Vol/bind632
Sider (fra-til)33-8
Antal sider6
ISSN0304-3940
DOI
StatusUdgivet - 6 okt. 2016

ID: 49774674